NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand

Journal of Immunology

Volumn 190, Issue 9, 2013, Pages 4650-4660

  Pittari, Gianfranco ^a   Liu, Xiao Rong ^a   Selvakumar, Annamalai ^a   Zhao, Zeguo ^a   Merino, Ernesto ^a   Huse, Morgan ^a   Chewning, Joseph H ^a,d   Hsu, Katharine C ^a,b   Dupont, Bo ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Weill Cornell Medical Center   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD94 ANTIGEN; HLA ANTIGEN CLASS 1; HLA C ANTIGEN; HLA C1 ANTIGEN; HLA C2 ANTIGEN; INTERLEUKIN 15; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS1; NATURAL KILLER CELL RECEPTOR NKG2A; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY REACTION; ANTIGEN FUNCTION; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; GENOTYPE; HETEROZYGOTE DETECTION; HOMOZYGOSITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE FUNCTION; MOLECULAR CLONING; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTIGENS, CD; DOWN-REGULATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-C ANTIGENS; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-15; KILLER CELLS, NATURAL; LIGANDS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, KIR; TISSUE DONORS;

EID: 84876812802     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202120     Document Type: Article

References (52)

1. Hogquist, K. A., T. A. Baldwin, and S. C. Jameson. 2005. Central tolerance: learning self-control in the thymus. Nat. Rev. Immunol. 5: 772-782. (Pubitemid 41400851)
2. Wardemann, H., S. Yurasov, A. Schaefer, J. W. Young, E. Meffre, and M. C. Nussenzweig. 2003. Predominant autoantibody production by early human B cell precursors. Science 301: 1374-1377. (Pubitemid 37075812)
3. Kärre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678. (Pubitemid 16119452)
4. Ljunggren, H. G., and K. Kärre. 1990. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 11: 237-244. (Pubitemid 20198988)
5. Karlhofer, F. M., R. K. Ribaudo, and W. M. Yokoyama. 1992. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 358: 66-70.
6. Daniels, B. F., F. M. Karlhofer, W. E. Seaman, and W. M. Yokoyama. 1994. A natural killer cell receptor specific for a major histocompatibility complex class I molecule. J. Exp. Med. 180: 687-692. (Pubitemid 24224146)
7. Ogasawara, K., J. Benjamin, R. Takaki, J. H. Phillips, and L. L. Lanier. 2005. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat. Immunol. 6: 938-945. (Pubitemid 43090449)
8. Oppenheim, D. E., S. J. Roberts, S. L. Clarke, R. Filler, J. M. Lewis, R. E. Tigelaar, M. Girardi, and A. C. Hayday. 2005. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotox-icity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 6: 928-937. (Pubitemid 43090448)
9. Wiemann, K., H. W. Mittrücker, U. Feger, S. A. Welte, W. M. Yokoyama, T. Spies, H. G. Rammensee, and A. Steinle. 2005. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J. Immunol. 175: 720-729. (Pubitemid 41094952)
10. Sun, J. C., and L. L. Lanier. 2008. Tolerance of NK cells encountering their viral ligand during development. J. Exp. Med. 205: 1819-1828.
11. Tripathy, S. K., P. A. Keyel, L. Yang, J. T. Pingel, T. P. Cheng, A. Schneeberger, and W. M. Yokoyama. 2008. Continuous engagement of a self-specific activation receptor induces NK cell tolerance. J. Exp. Med. 205: 1829-1841.
12. Zhao, Y., H. Ohdan, J. O. Manilay, and M. Sykes. 2003. NK cell tolerance in mixed allogeneic chimeras. J. Immunol. 170: 5398-5405. (Pubitemid 36617825)
13. Single, R. M., M. P. Martin, X. Gao, D. Meyer, M. Yeager, J. R. Kidd, K. K. Kidd, and M. Carrington. 2007. Global diversity and evidence for co-evolution of KIR and HLA. Nat. Genet. 39: 1114-1119. (Pubitemid 47342436)
14. Pende, D., S. Marcenaro, M. Falco, S. Martini, M. E. Bernardo, D. Montagna, E. Romeo, C. Cognet, M. Martinetti, R. Maccario, et al. 2009. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 113: 3119-3129.
15. Cognet, C., C. Farnarier, L. Gauthier, C. Frassati, P. André, A. Magérus-Chatinet, N. Anfossi, F. Rieux-Laucat, E. Vivier, and N. Schleinitz. 2010. Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cells. Clin. Immunol. 135: 26-32.
16. Fauriat, C., M. A. Ivarsson, H. G. Ljunggren, K. J. Malmberg, and J. Michaëlsson. 2010. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 115: 1166-1174.
17. Hsu, K. C., C. A. Keever-Taylor, A. Wilton, C. Pinto, G. Heller, K. Arkun, R. J. O'Reilly, M. M. Horowitz, and B. Dupont. 2005. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute mye-logenous leukemia predicted by KIR and HLA genotypes. Blood 105: 4878-4884. (Pubitemid 40807317)
18. Khakoo, S. I., and M. Carrington. 2006. KIR and disease: a model system or system of models? Immunol. Rev. 214: 186-201. (Pubitemid 44707911)
19. Chewning, J. H., C. N. Gudme, K. C. Hsu, A. Selvakumar, and B. Dupont. 2007. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR li-gand group in vitro. J. Immunol. 179: 854-868.
20. Trundley, A., H. Frebel, D. Jones, C. Chang, and J. Trowsdale. 2007. Allelic expression patterns of KIR3DS1 and 3DL1 using the Z27 and DX9 antibodies. Eur. J. Immunol. 37: 780-787. (Pubitemid 46916944)
21. Abeyweera, T. P., E. Merino, and M. Huse. 2011. Inhibitory signaling blocks activating receptor clustering and induces cytoskeletal retraction in natural killer cells. J. Cell Biol. 192: 675-690.
22. Uhrberg, M., N. M. Valiante, B. P. Shum, H. G. Shilling, K. Lienert-Weidenbach, B. Corliss, D. Tyan, L. L. Lanier, and P. Parham. 1997. Human diversity in killer cell inhibitory receptor genes. Immunity 7: 753-763. (Pubitemid 28064889)
23. Cooley, S., F. Xiao, M. Pitt, M. Gleason, V. McCullar, T. L. Bergemann, K. L. McQueen, L. A. Guethlein, P. Parham, and J. S. Miller. 2007. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 110: 578-586. (Pubitemid 47105396)
24. Dubois, S., J. Mariner, T. A. Waldmann, and Y. Tagaya. 2002. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17: 537-547. (Pubitemid 35351500)
25. Burkett, P. R., R. Koka, M. Chien, S. Chai, D. L. Boone, and A. Ma. 2004. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J. Exp. Med. 200: 825-834. (Pubitemid 39362919)
26. Koka, R., P. Burkett, M. Chien, S. Chai, D. L. Boone, and A. Ma. 2004. Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells. J. Immunol. 173: 3594-3598. (Pubitemid 39280717)
27. Huntington, N. D., H. Puthalakath, P. Gunn, E. Naik, E. M. Michalak, M. J. Smyth, H. Tabarias, M. A. Degli-Esposti, G. Dewson, S. N. Willis, et al. 2007. Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat. Immunol. 8: 856-863. (Pubitemid 47103041)
28. Colonna, M., F. Navarro, T. Bellón, M. Llano, P. García, J. Samaridis, L. Angman, M. Cella, and M. López-Botet. 1997. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med. 186: 1809-1818. (Pubitemid 27524591)
29. Vitale, M., R. Castriconi, S. Parolini, D. Pende, M. L. Hsu, L. Moretta, D. Cosman, and A. Moretta. 1999. The leukocyte Ig-like receptor (LIR)-1 for the cytomegalovirus UL18 protein displays a broad specificity for different HLA class I alleles: analysis of LIR-1 + NK cell clones. Int. Immunol. 11: 29-35. (Pubitemid 29037586)
30. Borges, L., M. L. Hsu, N. Fanger, M. Kubin, and D. Cosman. 1997. A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. J. Immunol. 159: 5192-5196. (Pubitemid 127470042)
31. Colonna, M., J. Samaridis, M. Cella, L. Angman, R. L. Allen, C. A. O'Callaghan, R. Dunbar, G. S. Ogg, V. Cerundolo, and A. Rolink. 1998. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J. Immunol. 160: 3096-3100. (Pubitemid 28164696)
32. Braud, V. M., D. S. Allan, C. A. O'Callaghan, K. Söderström, A. D'Andrea, G. S. Ogg, S. Lazetic, N. T. Young, J. I. Bell, J. H. Phillips, et al. 1998. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391: 795-799. (Pubitemid 28099678)
33. Lee, N., M. Llano, M. Carretero, A. Ishitani, F. Navarro, M. López-Botet, and D. E. Geraghty. 1998. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. USA 95: 5199-5204. (Pubitemid 28208575)
34. Foley, B., D. De Santis, L. Lathbury, F. Christiansen, and C. Witt. 2008. KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals. Int. Immunol. 20: 555-563. (Pubitemid 351426049)
35. Hsu, K. C., X. R. Liu, A. Selvakumar, E. Mickelson, R. J. O'Reilly, and B. Dupont. 2002. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework hap-lotypes, each with multiple subsets. J. Immunol. 169: 5118-5129. (Pubitemid 35217181)
36. Venstrom, J. M., G. Pittari, T. A. Gooley, J. H. Chewning, S. Spellman, M. Haagenson, M. M. Gallagher, M. Malkki, E. Petersdorf, B. Dupont, and K. C. Hsu. 2012. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N. Engl. J. Med. 367: 805-816.
37. Hanke, T., H. Takizawa, C. W. McMahon, D. H. Busch, E. G. Pamer, J. D. Miller, J. D. Altman, Y. Liu, D. Cado, F. A. Lemonnier, et al. 1999. Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. Immunity 11: 67-77. (Pubitemid 29359958)
38. George, T. C., J. R. Ortaldo, S. Lemieux, V. Kumar, and M. Bennett. 1999. Tolerance and alloreactivity of the Ly49D subset of murine NK cells. J. Immunol. 163: 1859-1867. (Pubitemid 29382186)
39. Kim, S., J. Poursine-Laurent, S. M. Truscott, L. Lybarger, Y. J. Song, L. Yang, A. R. French, J. B. Sunwoo, S. Lemieux, T. H. Hansen, and W. M. Yokoyama. 2005. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436: 709-713. (Pubitemid 41117274)
40. Anfossi, N., P. André, S. Guia, C. S. Falk, S. Roetynck, C. A. Stewart, V. Breso, C. Frassati, D. Reviron, D. Middleton, et al. 2006. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25: 331-342. (Pubitemid 44224147)
41. Elliott, J. M., J. A. Wahle, and W. M. Yokoyama. 2010. MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J. Exp. Med. 207: 2073-2079.
42. Joncker, N. T., N. Shifrin, F. Delebecque, and D. H. Raulet. 2010. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J. Exp. Med. 207: 2065-2072.
43. Biassoni, R., A. Pessino, A. Malaspina, C. Cantoni, C. Bottino, S. Sivori, L. Moretta, and A. Moretta. 1997. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur. J. Immunol. 27: 3095-3099. (Pubitemid 28018001)
44. Stewart, C. A., F. Laugier-Anfossi, F. Vély, X. Saulquin, J. Riedmuller, A. Tisserant, L. Gauthier, F. Romagné, G. Ferracci, F. A. Arosa, et al. 2005. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc. Natl. Acad. Sci. USA 102: 13224-13229. (Pubitemid 41325005)
45. Guia, S., B. N. Jaeger, S. Piatek, S. Mailfert, T. Trombik, A. Fenis, N. Chevrier, T. Walzer, Y. M. Kerdiles, D. Marguet, et al. 2011. Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance. Sci. Signal. 4: ra21.
46. Doucey, M. A., L. Scarpellino, J. Zimmer, P. Guillaume, I. F. Luescher, C. Bron, and W. Held. 2004. Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nat. Immunol. 5: 328-336. (Pubitemid 38332130)
47. Beilke, J. N., J. Benjamin, and L. L. Lanier. 2010. The requirement for NKG2D in NK cell-mediated rejection of parental bone marrow grafts is determined by MHC class I expressed by the graft recipient. Blood 116: 5208-5216.
48. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, et al. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100. (Pubitemid 34229476)
49. Sivori, S., S. Carlomagno, M. Falco, E. Romeo, L. Moretta, and A. Moretta. 2011. Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood 117: 4284-4292.
50. Druker, B. J., S. Tamura, E. Buchdunger, S. Ohno, G. M. Segal, S. Fanning, J. Zimmermann, and N. B. Lydon. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2: 561-566.
51. Boissel, N., D. Rea, V. Tieng, N. Dulphy, M. Brun, J. M. Cayuela, P. Rousselot, R. Tamouza, P. Le Bouteiller, F. X. Mahon, et al. 2006. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J. Immunol. 176: 5108-5116.
52. Alter, G., M. P. Martin, N. Teigen, W. H. Carr, T. J. Suscovich, A. Schneidewind, H. Streeck, M. Waring, A. Meier, C. Brander, et al. 2007. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 204: 3027-3036. (Pubitemid 350179568)